Free
Articles  |   July 2003
Weight of the Evidence in Statin Clinical Trials: Comparing the Results
Author Notes
  • Dr Clearfield is a professor of medicine and associate dean for clinical research at the University of North Texas Health Science Center at Fort Worth-Texas College of Osteopathic Medicine. Dr Clearfield represented the American Osteopathic Association, a member organization of the National Cholesterol Education Program Coordinating Committee, which approved the Third Report of the National Cholesterol Education Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Dr Clearfield is a member of the JAOA Editorial Advisory Board 
  • Address correspondence to Michael B. Clearfield, DO, FACOI, Department of Internal Medicine, University of North Texas Health Science Center at Fort Worth-Texas College of Medicine, 3500 Camp Bowie Blvd, Fort Worth, TX 76107-2644.E-mail: mclearfi@hsc.unt.edu 
Article Information
Cardiovascular Disorders / Preventive Medicine
Articles   |   July 2003
Weight of the Evidence in Statin Clinical Trials: Comparing the Results
The Journal of the American Osteopathic Association, July 2003, Vol. 103, S4-S11. doi:
The Journal of the American Osteopathic Association, July 2003, Vol. 103, S4-S11. doi:
Abstract

This review of lipid-lowering trials looks at both the primary and secondary prevention of coronary heart disease. It also introduces evidence pointing toward the emerging importance of nonlipid risk factors in the pathogenesis of atherosclerosis. This review is designed to enhance the primary care physician's working knowledge of the evidence supporting the importance of LDL-C reduction and the central role of statin therapy in the reduction of the risk of coronary heart disease, as well as provide a greater understanding of emerging risk factors.

 Dr Clearfield has served on speakers bureaus for AstraZeneca, Merck & Co, Pfizer Inc, and Sankyo Pharma Inc, and he has received grant/research support from AstraZeneca and Pfizer Inc.